Risk of dilution to existing shareholders from the exercise of stock options
First written in FY2021. 8 of 16 entries say "Materialised", first in FY2022-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026WorsenedAnnual report
「Series 22 Stock Acquisition Rights / 1 company employee / Common shares 7,800」
An additional 7,800 shares underlying Series 22 Stock Acquisition Rights were granted to 1 employee. In addition, 700 new shares were issued during the fiscal year as restricted stock compensation, increasing both potential and actual dilution exposure. - FY2026-H1WorsenedAnnual report
「21st series of stock acquisition rights」「Company employee 1」「Ordinary shares 8,300 shares」「Exercise period for the stock acquisition rights From 29 April 2027 To 28 April 2035」「Increase due to the issuance of new shares as restricted stock compensation.」
8,300 stock acquisition rights were added for 1 employee, and a further 700 shares were issued as restricted stock compensation, expanding both potential and actual dilution exposure. - FY2025-H1WorsenedAnnual report
「18th series of stock acquisition rights Class, description and number of shares underlying the stock acquisition rights Ordinary shares 1,087,000 shares」「19th series of stock acquisition rights Class, description and number of shares underlying the stock acquisition rights Ordinary shares 800,000 shares」「20th series of stock acquisition rights Class, description and number of shares underlying the stock acquisition rights Ordinary shares 500,000 shares」
The 18th through 20th series of stock acquisition rights, underlying a total of 2,387,000 shares, were added with UBS AG London Branch as the allottee. Potential dilution exposure increased substantially. - FY2024WorsenedAnnual report
「The increase in the total number of issued shares during the consolidated fiscal year consisted of 10,400 shares added through the exercise of stock options and 21,900 shares added through the issuance of new shares as restricted stock compensation.」
During the fiscal year, 10,400 shares were issued through the exercise of stock options and 21,900 restricted shares were issued. In addition, after the filing, the issuance of 55,400 shares under the 17th series of stock acquisition rights and 27,500 restricted shares for directors was disclosed, expanding potential dilution exposure. - FY2024-Q3MaterialisedAnnual report
「1 October 2023 to 31 December 2023 (Note) 2,600 35,681,112」
During the third quarter, 2,600 shares were added through the exercise of stock acquisition rights, and a share issuance that may result in dilution actually occurred. - FY2024-Q2WorsenedAnnual report
「16th series of stock acquisition rights」「Category and number of eligible grantees Company employees 6 Directors of subsidiaries 1」「Class, description and number of shares underlying the stock acquisition rights Ordinary shares 40,200」「Exercise period for the stock acquisition rights From 31 October 2025 To 30 October 2033」
Following the resolution of 30 October 2023, 40,200 stock acquisition rights were added for 6 employees and 1 subsidiary director. Future potential dilution exposure increased. - FY2024-Q1MaterialisedAnnual report
「Increase due to the exercise of each stock acquisition right.」「Increase due to a gratis allotment to third parties as restricted stock compensation.」
During the first quarter, 7,800 shares were added through the exercise of stock acquisition rights, and 21,900 restricted shares were also issued to 3 directors. Share issuances that may result in dilution actually occurred. - FY2023WorsenedAnnual report
「The Company resolved to allot stock acquisition rights as stock options to its employees.」「Company employees 67」「Ordinary shares 102,100 shares」
The 15th series of stock acquisition rights, resolved on 28 April 2023 and allotted on 19 May, created potential dilution exposure relating to 102,100 shares for 67 employees. - FY2023-Q3MaterialisedAnnual report
「1 October 2022 to 31 December 2022」「9,000」「Increase due to the exercise of stock acquisition rights.」
During the third quarter, 9,000 shares were added through the exercise of stock acquisition rights, and share issuances that may result in dilution continued to occur. - FY2023-Q2WorsenedAnnual report
「Category and number of eligible grantees Company employees 10」「Class, description and number of shares underlying the stock acquisition rights Ordinary shares 34,500」「Exercise period for the stock acquisition rights From 1 November 2024 To 31 October 2032」
The Company resolved to allot the 14th series of stock acquisition rights underlying 34,500 shares to 10 employees. Additional potential dilution exposure was created before exercise. - FY2023-Q1MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
From April to June 2022, 4,200 shares were added through the exercise of stock acquisition rights. In addition, 18,500 restricted shares were issued as share-based compensation, resulting in a share issuance that may lead to dilution. - FY2022MaterialisedAnnual report
「The increase of 35,617,312 ordinary shares was attributable to an increase of 17,742,456 shares through a share exchange, 17,800,456 shares through a stock split, 60,500 shares through the exercise of stock acquisition rights, and 13,900 shares through the delivery of restricted shares.」
During the fiscal year, 60,500 shares were added through the exercise of stock acquisition rights, and share issuances that may result in dilution continued to occur. - FY2022-Q3MaterialisedAnnual report
「1 October 2021 to 31 December 2021 Increase due to the exercise of stock acquisition rights.」
During the cumulative third quarter, 8,000 shares were added through the exercise of stock acquisition rights, and share issuances that may result in dilution continued to occur. - FY2022-Q2MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
Between 1 July and 30 September 2021, 43,200 shares were added through the exercise of stock acquisition rights. Share issuances that may result in dilution continue to occur. - FY2022-Q1MaterialisedAnnual report
「2 April 2021 to 30 June 2021 Increase due to the exercise of stock acquisition rights.」
700 shares were issued through the exercise of stock acquisition rights, and a share issuance associated with dilution risk actually occurred. - FY2021First statedAnnual report
「As of 1 June 2021, the potential number of shares represented by these stock acquisition rights was 305,300, equivalent to 1.7% of the 17,757,256 issued shares as of the same date.」
Granting stock acquisition rights to directors, officers and employees may dilute the value of shares and voting rights upon exercise.